Hizentra® CIDP - Key Publications | CSL Behring Medical Affairs

Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.

Product Information	Educational Materials	Conferences and Events	Key Publications

Posters

Safety of Decade Plus Use of IgPro20 in the Real World

View Poster

Please see full prescribing information for Hizentra

Budget Impact of Subcutaneous Immunoglobulin Intravenous Immunoglobulin and Efgartigimod Alfa in Patients With Chronic Inflammatory Demyelinating Polyneuropathy in the United States

View Poster

Please see full prescribing information for Hizentra

Successful simulation of infusion pump use for IgPro20 prefilled syringes

View Poster

Please see full prescribing information for Hizentra

Subcutaneous Immunoglobulin (IgPro20) Dose Adjustment for Chronic Inflammatory Demyelinating Polyneuropathy Maintenance Therapy in Clinical Practice

View Poster

Please see full prescribing information for Hizentra

Real-world experience of needle length use based on BMI for IgPro20 administration

View Poster

Please see full prescribing information for Hizentra

Key Publications

Subcutaneous Immunoglobulin for maintenance treatment in CIDP (PATH): a randomized, double-blind, placebo-controlled, phase 3 trial

van Schaik, IN et al
Lancet Neurol, 2017
Request | Ask a Question | View Article

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH study): study protocol for a randomized controlled trial.

van Schaik, IN et al
Trials, 2016
Request | Ask a Question | View Article

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP

Van Schaik, IN et al
Neurol NeuroimmunolNeuroinflamm, 2019
Request | Ask a Question | View Article